ABSTRACT:
The second most common cancer among women, after lung cancer, is breast cancer. The main form of treatment for the most prevalent subtype of breast cancer, hormone receptor (HR) positive, HER2 negative breast cancer, is endocrine therapy. Although there are various endocrine treatment medications available, virtually all metastatic HR-positive breast tumors will develop drug resistance to them. An essential method of resistance to aromatase drugs is represented by ESR1 mutations. As a potential therapy for ER+ breast cancer, Elacestrant is a new, non-steroidal, selective estrogen receptor degrader with complicated dose-related ER agonist/antagonist action. A brand-new oral selective estrogen receptor degrader (SERD), Elacestrant targets the estrogen receptor specifically on breast cancer cells to stop tumor growth. In patients with HR-positive, HER2-negative metastatic breast cancer, elacestrant showed a significant, albeit moderate, improvement in median progression-free survival (PFS) compared to standard of care endocrine therapy. Importantly, individuals with ESR1 mutations also benefited significantly, which prompted the FDA to approve Elacestrant for use in this patient population. Upper gastrointestinal symptoms were the most common side effects of Elacestrant, which was generally well tolerated. There are numerous current clinical trials assessing the effectiveness of Elacestrant in the treatment of metastatic breast cancer, both alone and in combination with other targeted therapies. The review will provide necessary details regarding Elacestrant.
Cite this article:
Amitkumar J. Vyas, Anjali Ramani, Ajay I. Patel. The Review of Chemistry, Pharmacological properties and Bio-analytical Methods of Oral selective Estrogen Receptor Degrader: Elacestrant. Asian Journal of Pharmaceutical Analysis. 2025;15(1):66-2. doi: 10.52711/2231-5675.2025.00011
Cite(Electronic):
Amitkumar J. Vyas, Anjali Ramani, Ajay I. Patel. The Review of Chemistry, Pharmacological properties and Bio-analytical Methods of Oral selective Estrogen Receptor Degrader: Elacestrant. Asian Journal of Pharmaceutical Analysis. 2025;15(1):66-2. doi: 10.52711/2231-5675.2025.00011 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2025-15-1-11
REFERENCES:
1. Orrantia‐Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L. E., Gómez-Valles, F. O., and Ramírez-Valdespino, C. A. Subtypes of breast cancer. In Exon Publications eBooks 2022; 31–42. doi: https://doi.org/10.36255/exon-publications-breast-cancer-subtypes
2. Hanker, A. B., Sudhan, D. R., and Arteaga, C. L. Overcoming endocrine resistance in breast cancer. Cancer Cell, 2020; 37(4), 496–513. https://doi.org/10.1016/j.ccell.2020.03.009
3. Cruskie, M. P., Jr. US20200361853A1 - Polymorphic forms of rad1901-2HCl - Google Patents. 2017; https://patents.google.com/patent/US20200361853A1/en?oq=US-2020361853-A1
4. Osborne, C. K., and Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annual Review of Medicine, 2011; 62(1), 233–247. https://doi.org/10.1146/annurev-med-070909-182917
5. Bihani, T., Patel, H., Arlt, H., Tao, N., Jiang, H., Brown, J. L., Purandare, D. M., Hattersley, G., and Garner, F. M. Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER+ breast cancer patient-derived xenograft models. Clinical Cancer Research, 2017; 23(16), 4793–4804. https://doi.org/10.1158/1078-0432.ccr-16-2561
6. Robertson, J. F. R., Bondarenko, I., Trishkina, E., Dvorkin, M., Panasci, L. C., Manikhas, A., Shparyk, Y., Cardona‐Huerta, S., Cheung, K., Philco-Salas, M. J., Ruíz‐Borrego, M., Shao, Z., Noguchi, S., Rowbottom, J., Stuart, M. K., Grinsted, L., Fazal, M., and Ellis, M. J. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet, 2016; 388(10063), 2997–3005. https://doi.org/10.1016/s0140-6736(16)32389-3
7. Wardell, S. E., Nelson, E. R., Chao, C. A., Alley, H. M., and McDonnell, D. P. Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. Endocrine-related Cancer, 2015; 22(5), 713–724. https://doi.org/10.1530/erc-15-0287
8. Garner, F. M., Shomali, M., Paquin, D., Lyttle, C. R., and Hattersley, G. RAD1901. Anti-Cancer Drugs, 2015; 26(9), 948–956. https://doi.org/10.1097/cad.0000000000000271
9. Patel, H., Tao, N., Lee, K. M., Huerta, M., Arlt, H., Mullarkey, T., Troy, S., Arteaga, C. L., andBihani, T. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. Breast Cancer Research, 2019; 21(1). https://doi.org/10.1186/s13058-019-1230-0
10. Patel, H., Tao, N., Arlt, H., andBihani, T. Abstract P6-20-08: Anti-tumor activity of elacestrant (RAD1901) in models harboring ESR1 mutations resistant to standard of care therapies. Cancer Research, 79(4_Supplement), P6-08. 2019; https://doi.org/10.1158/1538-7445.sabcs18-p6-20-08
11. Kaklamani, V., Bardia, A., Wilks, S., Weise, A., Richards, D. A., Harb, W. A., Osborne, C. R., Wesolowski, R., Karuturi, M. S., Conkling, P., Bagley, R. G., Jung, J., Bihani, T., Conlan, M. G., Kabos, P. Abstract PD7-07: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Cancer Research, 80(4_Supplement), PD7-07. 2020; https://doi.org/10.1158/1538-7445.sabcs19-pd7-07
12. Jager, A., De Vries, E. G., Van Oordt, C. W. M. D. H., Neven, P., Venema, C. M., Glaudemans, A. W. J. M., Wang, Y., Bagley, R. G., Conlan, M. G., Aftimos, P. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging. Breast Cancer Research, 2020; 22(1). https://doi.org/10.1186/s13058-020-01333-3
13. National Center for Biotechnology Information, PubChem Compound Summary for CID 23642301, Elacestrant. Retrieved August 26, 2023 from https://pubchem.ncbi.nlm.nih.gov/compound/Elacestrant.
14. Elacestrant: Uses, interactions, mechanism of action | DrugBank Online. DrugBank. https://go.drugbank.com/drugs/DB06374
15. Stemline Therapeutics Inc. ORSERDU™ (elacestrant) tablets, for oral use: US prescribing information. 2023. https://www.fda.gov/.
16. Cruskie, M. P., Jr. US20200361853A1 - Polymorphic forms of rad1901-2HCl - Google Patents.2017; https://patents.google.com/patent/US20200361853A1/en?oq=US-2020361853-A1
17. Cruskie, M. P. US20210269389A1 - Polymorphic forms of rad1901-2hcl - Google Patents.2018; https://patents.google.com/patent/US20210269389A1/en?oq=US20210269389-A1
18. Cruskie, M. P. US11643385B2 - Polymorphic forms of RAD1901-2HCl - Google Patents. 2018; https://patents.google.com/patent/US11643385B2/en?oq=US11643385-B2
19. Aragam, N. K. US20220117963A1 - Elacestrant in combination with abemaciclib in women with breast cancer - Google Patents. 2018; https://patents.google.com/patent/US20220117963A1/en?q=(Elacestrant)andoq=Elacestrant
20. Aragam, N. K. PH12021551235A1 - Elacestrant in combination with abemaciclib in women with breast cancer - Google Patents. 2018; https://patents.google.com/patent/PH12021551235A1/en?oq=PH-12021551235-A1
21. Kordic, L. WO2023064519A1 - Solid state forms of elacestrant and processes for preparation there of - Google Patents. 2021; https://patents.google.com/patent/WO2023064519A1/en?q=(Elacestrant)andoq=Elacestrant
22. Garner, F. CA2984195A1 - Use of rad1901 in the treatment of cancer - Google Patents. 2015; https://patents.google.com/patent/CA2984195A1/en?oq=CA2984195-A1A2984195A1
23. Lu, Y., Liu, W. Selective estrogen receptor degraders (SERDs): a promising strategy for estrogen receptor positive Endocrine-Resistant breast cancer. Journal of Medicinal Chemistry, 2020; 63(24), 15094–15114. https://doi.org/10.1021/acs.jmedchem.0c00913
24. Wang, L., Guillen, V. S., Sharma, N., Flessa, K., Min, J., Carlson, K. E., Toy, W., Braqi, S., Katzenellenbogen, B. S., Katzenellenbogen, J. A., Chandarlapaty, S., and Sharma, A. New class of selective estrogen receptor degraders (SERDs): expanding the toolbox of PROTAC degrons. ACS Medicinal Chemistry Letters, 2018; 9(8), 803–808. https://doi.org/10.1021/acsmedchemlett.8b00106
25. Shagufta, Ahmad, I., Mathew, S., and Rahman, S. Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer. RSC Medicinal Chemistry, 2020; 11(4), 438–454. https://doi.org/10.1039/c9md00570f
26. Bardia, A., Aftimos, P., Bihani, T., Anderson-Villaluz, A. T., Jung, J., Conlan, M. G., andKaklamani, V. EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Future Oncology, 2019; 15(28), 3209–3218. https://doi.org/10.2217/fon-2019-0370
27. Conlan, M. G., De Vries, E. F. J., Glaudemans, A. W. J. M., Wang, Y., and Troy, S. Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women. European Journal of Drug Metabolism and Pharmacokinetics, 2020; 45(5), 675–689. https://doi.org/10.1007/s13318-020-00635-3
28. Patel, H., andBihani, T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacology and Therapeutics, 2018; 186, 1–24. https://doi.org/10.1016/j.pharmthera.2017.12.012
29. Hoy, S. M. Elacestrant: First approval. Drugs, 2023; 83(6), 555–561. https://doi.org/10.1007/s40265-023-01861-0
30. Elacestrant oral: Uses, side effects, interactions, pictures, warnings and dosing - WebMD. https://www.webmd.com/drugs/2/drug-185885/elacestrant-oral/details
31. Elacestrant Interactions Checker. Drugs.com. https://www.drugs.com/drug-interactions/elacestrant
32. Tecnico, U. Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations. Menarini Corporate. 2023; https://www.menarini.com/en-us/news/news-detail/stemline-therapeutics-a-subsidiary-of-menarini-group-receives-us-fda-approval-for-orserdutm-elacestrant-as-the-first-and-only-treatment-specifically-indicated-for-patients-with-esr1-mutations
33. Livak, K. J., Schmittgen, T. D. Analysis of relative gene expression data using Real-Time Quantitative PCR and the 2−ΔΔCT method. Methods, 2001; 25(4), 402–408. https://doi.org/10.1006/meth.2001.1262